To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions

PharmacokineticsHealthy Subjects

Interventions

DRUG

mirabegron OCAS

oral

DRUG

Placebo

oral

Trial Locations (2)

Kendle Nederland, Utrecht

Pharma Bio Research, Zuidlaren